Ranbaxy Attacks Hyman Phelps' FDA Exclusivity Petition
Ranbaxy Inc. criticized Hyman Phelps & McNamara PC for pressuring the U.S. Food and Drug Administration to bar the Indian drugmaker from scoring market exclusivity for three generics, saying in a...To view the full article, register now.
Already a subscriber? Click here to view full article